Comments
Loading...
GSK Stock Guidance | NYSE:GSK | Benzinga
GSK issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/05/2025 | GSK | GSK | FY | 2025 | $2.09 | $2.13 | $4.52 | $40.07B | $40.85B | $34.29B | Get Alert |
| 10/30/2024 | GSK | GSK | FY | 2024 | $1.71 | $1.74 | $4.06 | $40.94B | $41.71B | $41.46B | Get Alert |
| 07/31/2024 | GSK | GSK | FY | 2024 | $1.71 | $1.74 | $4.04 | $40.94B | $41.71B | $40.67B | Get Alert |
| 05/01/2024 | GSK | GSK | FY | 2024 | $2.12 | $2.16 | $3.96 | $41.16B | $41.16B | $39.57B | Get Alert |
| 01/31/2024 | GSK | GSK | FY | 2024 | $1.64 | $1.69 | $4.05 | $39.53B | $40.29B | $39.82B | Get Alert |
| 11/01/2023 | GSK | GSK | FY | 2023 | $2.07 | $2.12 | $3.86 | $41.58B | $41.95B | $35.50B | Get Alert |
| 07/26/2023 | GSK | GSK | FY | 2023 | $1.99 | $2.05 | $3.80 | $39.63B | $40.37B | $37.43B | Get Alert |
| 04/26/2023 | GSK | GSK | FY | 2023 | $1.90 | $1.96 | $3.68 | $37.75B | $38.47B | $35.72B | Get Alert |
| 02/01/2023 | GSK | GSK | FY | 2023 | $1.94 | $1.99 | $3.64 | $38.54B | $39.27B | $35.92B | Get Alert |
| 11/02/2022 | GSK | GSK | FY | 2022 | — | — | — | $50.67B | $51.60B | $32.29B | Get Alert |
| 07/27/2022 | GSK | GSK | FY | 2022 | — | — | — | $49.73B | $50.67B | $38.72B | Get Alert |
| 10/27/2021 | GSK | GlaxoSmithKline | FY | 2021 | $1.56 | $1.59 | $2.86 | — | — | — | Get Alert |
| 07/29/2020 | GSK | GSK | FY | 2020 | $1.56 | $1.60 | $2.99 | — | — | — | Get Alert |
FAQ
What is the most recent guidance for GSK (GSK)?
The most recent guidance for GSK (GSK) was reported on February 5, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $2.09 to $2.13, compared to the estimated EPS of $4.52. Additionally, GSK forecasted revenue between $40.07B and $40.85B for the quarter.
Browse guidance and forecast on all stocks.